JP Morgan Maintains Overweight on Adarx Pharmaceuticals, Lowers Price Target to $36

Benzinga · 2d ago
JP Morgan analyst Tessa Romero maintains Adarx Pharmaceuticals (NASDAQ:ADRX) with a Overweight and lowers the price target from $38 to $36.